SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Amphivena Therapeutics Inc., a privately held biotechnology company developing a novel CD33/CD3 T cell engager for the treatment of Acute Myeloid Leukemia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback